In fact, Nerinetide (NA-1), a neuroprotectant focused on the inhibition of PSD-95 implicated in the excitotoxic process developed after stroke, has been shown to improve outcomes in a subpopulation of patients with AIS when administered in combination with EVT [ESCAPE-NA1 trial (19)]. Here, DLG4 is linked to androgen insensitivity syndrome.